IS7492A - Lyfjablöndu uppskriftir, sem innifela melantónín - Google Patents

Lyfjablöndu uppskriftir, sem innifela melantónín

Info

Publication number
IS7492A
IS7492A IS7492A IS7492A IS7492A IS 7492 A IS7492 A IS 7492A IS 7492 A IS7492 A IS 7492A IS 7492 A IS7492 A IS 7492A IS 7492 A IS7492 A IS 7492A
Authority
IS
Iceland
Prior art keywords
melantonin
pharmaceutical preparation
preparation recipes
recipes
barbiturate
Prior art date
Application number
IS7492A
Other languages
English (en)
Other versions
IS2858B (is
Inventor
Zisapel Nava
Original Assignee
Neurim Pharmaceuticals (1991) Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29227410&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS7492(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neurim Pharmaceuticals (1991) Ltd. filed Critical Neurim Pharmaceuticals (1991) Ltd.
Publication of IS7492A publication Critical patent/IS7492A/is
Publication of IS2858B publication Critical patent/IS2858B/is

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IS7492A 2002-04-28 2004-10-07 Lyfjasamsetning sem nær yfir melatónín IS2858B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL149377A IL149377A (en) 2002-04-28 2002-04-28 Pharmaceutical formulation comprising melatonin for the potentiation of the effect of hypnotic compounds
PCT/IL2003/000240 WO2003086352A1 (en) 2002-04-08 2003-03-20 Pharmaceutical formulation comprising melatonin

Publications (2)

Publication Number Publication Date
IS7492A true IS7492A (is) 2004-10-07
IS2858B IS2858B (is) 2013-12-15

Family

ID=29227410

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7492A IS2858B (is) 2002-04-28 2004-10-07 Lyfjasamsetning sem nær yfir melatónín

Country Status (30)

Country Link
US (1) US20050175692A1 (is)
EP (1) EP1494650B1 (is)
JP (1) JP2005527583A (is)
KR (1) KR101000624B1 (is)
CN (1) CN100386070C (is)
AR (1) AR039232A1 (is)
AT (1) ATE507831T1 (is)
AU (1) AU2003227304B2 (is)
BR (1) BR0308762A (is)
CA (1) CA2477516C (is)
DE (1) DE60336999D1 (is)
DK (1) DK1494650T3 (is)
EA (1) EA007954B1 (is)
ES (1) ES2366116T3 (is)
GT (1) GT200300064A (is)
HK (1) HK1075616A1 (is)
HN (1) HN2003000115A (is)
IL (1) IL149377A (is)
IS (1) IS2858B (is)
MX (1) MXPA04009893A (is)
NO (1) NO332525B1 (is)
NZ (1) NZ536298A (is)
PE (1) PE20040161A1 (is)
PL (1) PL209922B1 (is)
PT (1) PT1494650E (is)
TW (1) TW200305404A (is)
UA (1) UA86924C2 (is)
UY (1) UY27753A1 (is)
WO (1) WO2003086352A1 (is)
ZA (1) ZA200407563B (is)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004308962A1 (en) * 2003-12-24 2005-07-14 Sepracor Inc. Melatonin combination therapy for improving sleep quality
TW200626137A (en) * 2004-12-13 2006-08-01 Takeda Pharmaceuticals Co Preventive or therapeutic agent for sleep disorder
US20060198872A1 (en) * 2005-03-07 2006-09-07 Chioma Ikonte Plant based dietary supplement for improving the duration and quality of sleep
KR20070070307A (ko) * 2005-08-24 2007-07-04 에스에스 세야쿠 가부시키 가이샤 수면 개선 의약 조성물
CN1299680C (zh) * 2005-08-29 2007-02-14 陈彦方 一种治疗失眠的黑白制剂
AR056076A1 (es) * 2005-09-20 2007-09-19 Takeda Pharmaceutical Agente profilactico o terapeutico para el desorden de sueno
CN102018681A (zh) * 2010-12-10 2011-04-20 荣港生技医药科技(北京)有限公司 一种美乐托宁缓释剂、其制备方法及其应用
WO2012103411A2 (en) 2011-01-28 2012-08-02 Zx Pharma, Llc Controlled-release melatonin composition and related methods
US9532952B2 (en) * 2011-01-28 2017-01-03 Physician's Seal, LLC Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
EP2570126B1 (en) 2011-09-16 2014-03-26 Darius Rassoulian Use of melatonin for treating acute alcohol intoxication
WO2018078429A1 (en) * 2016-10-31 2018-05-03 Neurim Pharmaceuticals Ltd. Melatonin mini-tablets and method of manufacturing the same
US10849856B2 (en) 2016-10-31 2020-12-01 Neurim Pharmaceuticals Ltd. Melatonin mini-tablets and method of manufacturing the same
CN109364031A (zh) * 2018-10-07 2019-02-22 威海贯标信息科技有限公司 一种盐酸曲唑酮片剂组合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4600723A (en) * 1983-05-18 1986-07-15 Monash University Method for minimizing disturbances in circadian rhythms of bodily performance and function
US5707652A (en) * 1990-12-04 1998-01-13 State Of Oregon Methods of treating circadian rhythm phase disorders
IT1251544B (it) * 1991-05-13 1995-05-17 Gabriele Biella Composizioni farmaceutiche attive nella terapia dei disturbi del sonno comprendenti melatonina o un suo derivato in associazione con un derivato benzodiazepinico
FR2718020B1 (fr) * 1994-04-01 1996-05-31 Biotec Centre Sa Composition galénique mucoadhésive hétérofonctionnelle.
MD1716C2 (ro) * 1995-02-01 2002-02-28 Neurim Pharmaceuticals (1991) Ltd. Utilizare a melatoninei pentru tratamentul pacienţilor dependenţi de benzodiazepine
PL188093B1 (pl) * 1996-03-08 2004-12-31 Takeda Chemical Industries Ltd Związek trójpierścieniowy, sposób jego wytwarzania i zastosowanie, kompozycja farmaceutyczna oraz związki pośrednie
AU2583397A (en) * 1996-04-10 1997-10-29 Chronorx, Llc Unit dosage forms, containing magnesium, vitamin c, vitamin e, folate and selenium, for treatment of vasoconstriction and related conditions
AU3716997A (en) * 1996-07-17 1998-02-09 Merck & Co., Inc. Alteration of circadian rhythmicity with a tachykinin antagonist
AU4060599A (en) * 1998-06-09 1999-12-30 Takeda Chemical Industries Ltd. Pharmaceutical composition for treating or preventing sleep disorders
CN1131030C (zh) * 1999-03-18 2003-12-17 胡秀云 一种由褪黑素和安定制成的调节睡眠的组合物
WO2000056303A2 (en) 1999-03-22 2000-09-28 Immugen Pharmaceuticals, Inc. Treatment of immune diseases
IL144900A (en) * 2001-08-14 2013-12-31 Neurim Pharma 1991 Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs

Also Published As

Publication number Publication date
AU2003227304A1 (en) 2003-10-27
EP1494650A4 (en) 2006-07-12
NZ536298A (en) 2008-09-26
AU2003227304B2 (en) 2007-12-06
UY27753A1 (es) 2003-05-30
CA2477516A1 (en) 2003-10-23
WO2003086352A1 (en) 2003-10-23
CN1646098A (zh) 2005-07-27
ZA200407563B (en) 2005-11-30
IL149377A (en) 2012-10-31
PL209922B1 (pl) 2011-11-30
TW200305404A (en) 2003-11-01
CN100386070C (zh) 2008-05-07
NO20043576L (no) 2004-12-22
EA007954B1 (ru) 2007-02-27
UA86924C2 (ru) 2009-06-10
DK1494650T3 (da) 2011-08-08
KR101000624B1 (ko) 2010-12-10
ATE507831T1 (de) 2011-05-15
US20050175692A1 (en) 2005-08-11
EP1494650B1 (en) 2011-05-04
PT1494650E (pt) 2011-08-18
AU2003227304A2 (en) 2005-04-14
HN2003000115A (es) 2004-04-20
PE20040161A1 (es) 2004-03-22
DE60336999D1 (de) 2011-06-16
GT200300064A (es) 2003-11-26
MXPA04009893A (es) 2005-06-17
JP2005527583A (ja) 2005-09-15
IS2858B (is) 2013-12-15
AR039232A1 (es) 2005-02-09
EP1494650A1 (en) 2005-01-12
CA2477516C (en) 2012-12-11
KR20040101406A (ko) 2004-12-02
PL372867A1 (en) 2005-08-08
BR0308762A (pt) 2005-01-11
NO332525B1 (no) 2012-10-08
EA200401331A1 (ru) 2005-04-28
ES2366116T3 (es) 2011-10-17
IL149377A0 (en) 2009-02-11
HK1075616A1 (en) 2005-12-23

Similar Documents

Publication Publication Date Title
HK1075616A1 (en) Pharmaceutical formulation comprising melatonin
NO20053042L (no) Anvendelse av spongosin (2-metoksyadenosin) for behandling av smerte, saerlig hyperalgesi.
DE60327103D1 (de) Darreichungsformen enthaltend einen protonpumphemmer, einen nsaid und einen puffer
PA8539901A1 (es) Novedosa sal de succinato de o-desmetil-venlafaxina
MXPA03010134A (es) Derivados de ciclohexan-1-4-diamina sustituidos.
MXPA03007140A (es) Derivados de carbolina.
NO20062504L (no) Sammensetninger og doseringsformer for forbedret absorpsjon
BRPI0415639A (pt) formas de dosagem de oxicodona de liberação controlada, oral, uma vez por dia
WO2003075857A3 (en) Amino-methyl substituted tetracycline compounds
NO20052761L (no) Spirocykliske cykloheksanderivater.
DK1654253T3 (da) Substituerede 3-pyrrolidinindolderivater
NO20052058D0 (no) Behandling av influensa.
HK1086832A1 (en) Substituted benzosulphonamides as potentiators of glutamate receptors
SG146442A1 (en) Sulphonamide derivatives, their preparation and use as medicaments
SE0301653D0 (sv) Novel compounds
CO5660287A2 (es) Derivados de tetrahidrocarbazol y su uso farmaceutico
MY142044A (en) Endoparasiticidal compositions for topical application
BRPI0415709A (pt) esquemas terapêuticos para antagonistas de baff
MY135829A (en) Analeptic and drug combinations
WO2005032490A3 (en) Cyclic diamines and derivatives as factor xa inhibitors
CL2004000877A1 (es) Combinacion farmaceutica que comprende 8a) melatonina y agonistas de la melatonina, y nicotina y agonistas receptores de nicotina; kit farmaceutico, y; uso en el tratamiento de insomnio, dificultades cognitivas y dificultades de memoria; kit farmaceu
EA200300727A1 (ru) Производные 2h-1-бензопирана, способы их получения и их фармацевтические композиции
DE60224667D1 (de) Perylenequinonen zur anwendung als sonosensitizer
CY1109803T1 (el) Φαρμακευτικες συνθεσεις που βασιζονται σε ανταγωνιστες νκ2 για παιδιατρικη χρηση
TR200302134T4 (tr) 2-metil-tiazolidin-2,4-dikarboksilik asit ve/veya bunun fizyolojik olarak uygun tuzlarının anti-kanser ajanları olarak kullanımı.